Frontlight ResearchEarly access
TerminatedPhase 2
Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma
Key facts
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 16 people enrolled
- Started
- 15 Jan 2021
- Ended
- 4 Aug 2025
- Type of study
- Interventional
- Treatments tested
- Anlotinib
- Record updated
- 18 November 2026
- Why it stopped
- The trial was terminated early because free anlotinib was no longer available for newly enrolled patients.
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Aged 18-70 years,
- Histologically proven diagnosis of glioblastoma (WHO grade IV),
- Have received standard STUPP treatment plan,
- Gross resection or partial resection of the tumor (confirmed by MRI)> 50%,
- The pathological tissue specimens are detected as MGMT unmethylated,6.Karnofsky performance status ≥ 60,
- No previous radiotherapy, chemotherapy, immunotherapy or biotherapy 7.Adequate bone marrow function: Hemoglobin ≥ 100g/L,Platelets ≥ 80×109/L,Absolute neutrophil count (ANC) ≥ 1.5×109/L; 8.Adequate renal function: Serum creatinine ≤ 1.25 x UNL (upper normal limit) or creatinine clearance ≥ 60 ml/min 9.Adequate hepatic function: serum bilirubin ≤ 1.5 x UNL, AST and ALT ≤ 2.5 x UNL,ALP≤5x UNL 10.For females of child-bearing potential, negative serum pregnancy test within 14 days prior to registration. Women of childbearing potential and male participants must practice adequate contraception during participation in the study and within 8 weeks after the last administration of the drug 11.Able to provide written informed consent
Who cannot take part
- Have received radiotherapy, chemotherapy or other anti-tumor drugs for the disease before surgery
- Previously received radiation therapy for the head and neck cancer
- Have received any antibody treatment before
- Recurrent or multiple malignant gliomas
- Contraindication of radiotherapy and chemotherapy defined as follows: Acute bacterial or fungal infection,Unstable angina and/or congestive heart failure within the last 6 months,co-morbidity with immunosuppressive therapy
- Evidence of bleeding diathesis or coagulopathy
- Prior invasive malignancy (except for non-melanomatous skin cancer or carcinoma in situ of cervix)
- Subtentorial glioblastoma or metastatic lesions outside the skull
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.
The group in the trial
- ExperimentalTreatment being tested
For MGMT unmethylated glioblastoma, during temozolomide adjuvant, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14)
Treatment: Anlotinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Anlotinib Combined With STUPP Protocol as First-line Regimen for MGMT Nonmethylated Glioblastoma: a Multicenter, Open-label, Single-arm, Phase II Clinical Trial
- Record updated
- 18 November 2026